Serum galectin-3 level in systemic sclerosis

Clinical Rheumatology

Volumn 33, Issue 2, 2014, Pages 215-220

  Koca, Suleyman Serdar ^a   Akbas, Fatma ^a   Ozgen, Metin ^a   Yolbas, Servet ^a   Ilhan, Nevin ^a   Gundogdu, Baris ^a   Isik, Ahmet ^a  

^a FIRAT UNIVERSITY   (Turkey)

Author keywords

Disease activity; Galectin 3; Systemic sclerosis

Indexed keywords

ADULT; BIOLOGICAL MARKERS; FEMALE; FIBROBLASTS; FIBROSIS; GALECTIN 3; HEALTHY VOLUNTEERS; HUMANS; INFLAMMATION; INTERLEUKIN-6; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; SCLERODERMA, SYSTEMIC; TRANSFORMING GROWTH FACTOR BETA1; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84893904556     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-013-2346-8     Document Type: Article

References (38)

1. Gabrielli A, Avvedimento EV, Krieg T (2009) Scleroderma. N Engl J Med 360(19):1989-2003
2. Rabquer BJ, Koch AE (2012) Angiogenesis and vasculopathy in systemic sclerosis: evolving concepts. Curr Rheumatol Rep 14(1):56-63
3. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, Rowell N, Wollheim F (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15(2):202-5
4. LeRoy EC (1974) Increased collagen synthesis by scleroderma skin fibroblasts in vitro: a possible defect in the regulation or activation of the scleroderma fibroblast. J Clin Invest 54(4):880-9
5. Henderson NC, Sethi T (2009) The regulation of inflammation by galectin-3. Immunol Rev 230(1):160-71
6. Barondes SH, Cooper DN, Gitt MA, Leffler H (1994) Galectins. Structure and function of a large family of animal lectins. J Biol Chem 269(33):20807-10
7. Ho MK, Springer TA (1982) Mac-2, a novel 32,000 Mr mouse macrophage subpopulation-specific antigen defined by monoclonal antibodies. J Immunol 128(3):1221-8
8. Hirabayashi J, Hashidate T, Arata Y, Nishi N, Nakamura T, Hirashima M, Urashima T, Oka T, Futai M, Muller WE, Yagi F, Kasai K (2002) Oligosaccharide specificity of galectins: a search by frontal affinity chromatography. Biochim Biophys Acta 1572(2-3):232-54
9. Dhirapong A, Lleo A, Leung P, Gershwin ME, Liu FT (2009) The immunological potential of galectin-1 and -3. Autoimmun Rev 8(5):360-3
10. Nishi Y, Sano H, Kawashima T, Okada T, Kuroda T, Kikkawa K, Kawashima S, Tanabe M, Goto T, Matsuzawa Y, Matsumura R, Tomioka H, Liu FT, Shirai K (2007) Role of galectin-3 in human pulmonary fibrosis. Allergol Int 56(1):57-65
11. Henderson NC, Mackinnon AC, Farnworth SL, Poirier F, Russo FP, Iredale JP, Haslett C, Simpson KJ, Sethi T (2006) Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc Natl Acad Sci 103(13):5060-5
12. Hochberg MC (1997) Update of the 1982 American College of Rheumatology Revised Criteria for Classification of Systemic Lupus Erythematosus. Arthritis Rheum 40:1725
13. Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23(5):581-90
14. Valentini G, Della Rossa A, Bombardieri S, Bencivelli W, Silman AJ, D'Angelo S, Cerinic MM, Belch JF, Black CM, Bruhlmann P, Czirják L, De Luca A, Drosos AA, Ferri C, Gabrielli A, Giacomelli R, Hayem G, Inanc M, McHugh NJ, Nielsen H, Rosada M, Scorza R, Stork J, Sysa A, van den Hoogen FH, Vlachoyiannopoulos PJ (2001) European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis 60(6):592-8
15. Medsger TA Jr, Silman AJ, Steen VD, Black CM, Akesson A, Bacon PA, Harris CA, Jablonska S, Jayson MI, Jimenez SA, Krieg T, Leroy EC, Maddison PJ, Russell ML, Schachter RK, Wollheim FA, Zacharaie H (1999) A disease severity scale for systemic sclerosis: development and testing. J Rheumatol 26(10):2159-67
16. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH (1992) Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 35(6):630-40
17. Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, Bacon P, Bombardieri S, Hanly J, Hay E, Isenberg D, Jones J, Kalunian K, Maddison P, Nived O, Petri M, Richter M, Sanchez-Guerrero J, Snaith M, Sturfelt G, Symmons D, Zoma A (1996) The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 39(3):363-9
18. Abrahamowicz M, Fortin PR, du Berger R, Nayak V, Neville C, Liang MH (1998) The relationship between disease activity and expert physician's decision to start major treatment in active systemic lupus erythematosus: a decision aid for development of entry criteria for clinical trials. J Rheumatol 25(2):277-84
19. Castro SV, Jimenez SA (2010) Biomarkers in systemic sclerosis. Biomark Med 4(1):133-47
20. Moinzadeh P, Denton CP, Abraham D, Ong V, Hunzelmann N, Eckes B, Krieg T (2012) Biomarkers for skin involvement and fibrotic activity in scleroderma. J Eur Acad Dermatol Venereol 26(3):267-76
21. Abraham DJ, Krieg T, Distler J, Distler O (2009) Overview of pathogenesis of systemic sclerosis. Rheumatology 48:iii3-iii7
22. Shi-Wen X, Denton CP, Dashwood MR, Holmes AM, Bou-Gharios G, Pearson JD, Black CM, Abraham DJ (2001) Fibroblast matrix gene expression and connective tissue remodeling: role of endothelin-1. J Invest Dermatol 116(3):417-25
23. Dragomir AC, Sun R, Mishin V, Hall LB, Laskin JD, Laskin DL (2012) Role of galectin-3 in acetaminophen-induced hepatotoxicity and inflammatory mediator production. Toxicol Sci 127(2):609-19
24. Calvier L, Miana M, Reboul P, Cachofeiro V, Martinez-Martinez E, de Boer RA, Poirier F, Lacolley P, Zannad F, Rossignol P, López-Andrés N (2013) Galectin-3 mediates aldosterone-induced vascular fibrosis. Arterioscler Thromb Vasc Biol 33(1):67-75
25. Colnot C, Ripoche MA, Milon G, Montagutelli X, Crocker PR, Poirier F (1998) Maintenance of granulocyte numbers during acute peritonitis is defective in galectin-3-null mutant mice. Immunology 94(3):290-6
26. Hsu DK, Yang RY, Pan Z, Yu L, Salomon DR, Fung-Leung WP, Liu FT (2000) Targeted disruption of the galectin-3 gene results in attenuated peritoneal inflammatory responses. Am J Pathol 156(3):1073-83
27. Nieminen J, St-Pierre C, Bhaumik P, Poirier F, Sato S (2008) Role of galectin-3 in leukocyte recruitment in a murine model of lung infection by Streptococcus pneumoniae. J Immunol 180(4):2466-73
28. Ohshima S, Kuchen S, Seemayer CA, Kyburz D, Hirt A, Klinzing S, Michel BA, Gay RE, Liu FT, Gay S, Neidhart M (2003) Galectin 3 and its binding protein in rheumatoid arthritis. Arthritis Rheum 48(10):2788-95
29. Lee YJ, Kang SW, Song JK, Park JJ, Bae YD, Lee EY, Lee EB, Song YW (2007) Serum galectin-3 and galectin-3 binding protein levels in Behçet's disease and their association with disease activity. Clin Exp Rheumatol 25(4 Suppl 45):S41-5
30. Kang EH, Moon KC, Lee EY, Lee YJ, Lee EB, Ahn C, Song YW (2009) Renal expression of galectin-3 in systemic lupus erythematosus patients with nephritis. Lupus 18(1):22-8
31. Okamura DM, Pasichnyk K, Lopez-Guisa JM, Collins S, Hsu DK, Liu FT, Eddy AA (2011) Galectin-3 preserves renal tubules and modulates extracellular matrix remodeling in progressive fibrosis. Am J Physiol Renal Physiol 300(1):F245-53
32. Mackinnon AC, Gibbons MA, Farnworth SL, Leffler H, Nilsson UJ, Delaine T, Simpson AJ, Forbes SJ, Hirani N, Gauldie J, Sethi T (2012) Regulation of transforming growth factor-β1-driven lung fibrosis by galectin-3. Am J Respir Crit Care Med 185(5):537-46
33. Taniguchi T, Asano Y, Akamata K, Noda S, Masui Y, Yamada D, Takahashi T, Ichimura Y, Toyama T, Tamaki Z, Tada Y, Sugaya M, Kadono T, Sato S (2012) Serum levels of galectin-3: possible association with fibrosis, aberrant angiogenesis, and immune activation in patients with systemic sclerosis. J Rheumatol 39(3):539-44
34. Hudson M, Steele R, Canadian Scleroderma Research Group (CSRG), Baron M (2007) Update on indices of disease activity in systemic sclerosis. Semin Arthritis Rheum 37(2):93-8
35. Medsger TA Jr (2003) Natural history of systemic sclerosis and the assessment of disease activity, severity, functional status, and psycho logic well-being. Rheum Dis Clin North Am 29(2):255-73
36. Valentini G, Silman AJ, Veale D (2003) Assessment of disease activity. Clin Exp Rheumatol 21:S39-41
37. Clements PJ (1995) Measuring disease activity and severity in scleroderma. Curr Opin Rheumatol 7(6):517-21
38. Hummers LK (2010) The current state of biomarkers in systemic sclerosis. Curr Rheumatol Rep 12(1):34-9